Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and
pharmacodynamics of INCB099318 in select solid tumors.
Miscellaneous, Phase I
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
INCB099318
Berlin, Jordan
National
Vanderbilt University
01-11-2022
Treatment
VICCPHI2136
NCT04272034

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Must have disease progression after treatment with available therapies that are known to confer clinical benefit or must be intolerant to or ineligible for standard treatment.

Histologically confirmed advanced solid tumors (protocol-defined select solid tumors) with measurable lesions per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) that are considered nonamenable to surgery or other curative treatments or procedures.

ECOG performance status score of 0 or 1.

Life expectancy > 12 weeks.

Willingness to avoid pregnancy or fathering children.



Exclusion Criteria:

Laboratory values outside the Protocol-defined ranges.

Clinically significant cardiac disease.

History or presence of an ECG that, in the investigator's opinion, is clinically meaningful.

Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases).

Known additional malignancy that is progressing or requires active treatment.

Has not recovered to Grade 1 or baseline from toxic effects of prior therapy (including prior IO) and/or complications from prior surgical intervention before starting study treatment.

Prior receipt of an anti-PD-L1 therapy.

Treatment with anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.

A 28-day washout for systemic antibiotics is required.

Probiotic usage while on study and during screening is prohibited.

Active infection requiring systemic therapy.

Known history of HIV

Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

To learn more about any of our clinical
trials, call 615-936-8422.